Peptide handling
LL-37 reconstitution calculator
Reconstitution calculator for LL-37, prefilled for its 5 and 10 mg vials. Get the concentration, the dose volume and the U-100 syringe reading.
Start from a compound
Fills the vial size and a starting water volume. Only compounds with a citable range fill a dose.
The second is the question asked once the syringe is already filled, or when checking a vial someone else reconstituted.
1 mg = 1,000 mcg. Published figures are usually micrograms; vial labels are milligrams.
- Draw to
- 4 unitson a U-100 syringe
- Dose
- 100 mcg
- Dose volume
- 0.04 mL
- Concentration
- 2.5 mg/mL
- Per unit
- 25 mcg
- Doses per vial
- 50whole doses; a partial one is not counted
Shown on a 30-unit (0.3 mL) U-100 syringe, the smallest that holds this draw.
LL-37 — Limited human data
From human studies that are small, early-phase, or for a different indication than the one this range is usually cited for. The prefilled dose is the low end of that range, daily; the cited human trial evaluated topical, not injectable, application.
Vial size and water volume are a starting point for the arithmetic, not a recommendation.
Adding more water makes the same dose a larger, easier-to-read mark on the syringe. It does not change how many doses the vial holds.
Vial sizes and starting volume
LL-37 is commonly supplied in 5 mg and 10 mg vials. The calculator opens on a 5 mg vial with 2 mL of bacteriostatic water — a starting point for the arithmetic, not a recommendation. Change either and everything recalculates.
That combination gives 2.5 mg/mL, so one insulin unit holds 25 mcg and a 100 mcg dose is 4 units.
What dose to enter
A range of 100–500 mcg per dose can be cited for LL-37, daily; the cited human trial evaluated topical, not injectable, application. The dose field opens at the low end of it.
Limited human data
From human studies that are small, early-phase, or for a different indication than the one this range is usually cited for.
- Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial. — Human randomized controlled trial. The verifying human trial behind this compound's tier. It is a topical wound treatment, not an injectable dosing study.
- Unique features of human cathelicidin LL-37. — Review. Reviews LL-37 biology; no dosing data.
- LL-37: Structures, Antimicrobial Activity, and Influence on Amyloid-Related Diseases. — Review. Structural and mechanistic review; no dosing data.
- The Antimicrobial Peptide Cathelicidin Exerts Immunomodulatory Effects via Scavenger Receptors. — Preclinical mechanistic study. Mechanistic immunology work; no dosing data.
- Evaluation of the effects of peptide antibiotics human beta-defensins and LL-37 on histamine release and prostaglandin D2 production from mast cells. — In vitro mechanistic study. In vitro mast-cell study; no dosing data.
Related
- LL-37 — the product page, with its current batch.
- Bacteriostatic water — what goes in the vial.
- Peptide reconstitution calculator — the general version, with the blend and half-life calculators alongside it.
- Dosing reference — published schedules, each with the evidence behind it.
For research use only. This tool performs arithmetic on figures you supply — it is not medical guidance and does not recommend a dose for any compound.